AU2003268096A1 - ANTISENSE MODULATION OF Nav1.3 EXPRESSION - Google Patents

ANTISENSE MODULATION OF Nav1.3 EXPRESSION

Info

Publication number
AU2003268096A1
AU2003268096A1 AU2003268096A AU2003268096A AU2003268096A1 AU 2003268096 A1 AU2003268096 A1 AU 2003268096A1 AU 2003268096 A AU2003268096 A AU 2003268096A AU 2003268096 A AU2003268096 A AU 2003268096A AU 2003268096 A1 AU2003268096 A1 AU 2003268096A1
Authority
AU
Australia
Prior art keywords
expression
antisense modulation
antisense
modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003268096A
Other languages
English (en)
Other versions
AU2003268096A8 (en
Inventor
Steven L. Roberds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2003268096A8 publication Critical patent/AU2003268096A8/xx
Publication of AU2003268096A1 publication Critical patent/AU2003268096A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003268096A 2002-08-14 2003-08-14 ANTISENSE MODULATION OF Nav1.3 EXPRESSION Abandoned AU2003268096A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40341602P 2002-08-14 2002-08-14
US60/403,416 2002-08-14
PCT/US2003/025465 WO2004016754A2 (fr) 2002-08-14 2003-08-14 Modulation antisens de l'expression de nav1.3

Publications (2)

Publication Number Publication Date
AU2003268096A8 AU2003268096A8 (en) 2004-03-03
AU2003268096A1 true AU2003268096A1 (en) 2004-03-03

Family

ID=31888234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003268096A Abandoned AU2003268096A1 (en) 2002-08-14 2003-08-14 ANTISENSE MODULATION OF Nav1.3 EXPRESSION

Country Status (7)

Country Link
EP (1) EP1578927A2 (fr)
JP (1) JP2006507808A (fr)
AU (1) AU2003268096A1 (fr)
BR (1) BR0313455A (fr)
CA (1) CA2495398A1 (fr)
MX (1) MXPA05001836A (fr)
WO (1) WO2004016754A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1687410A4 (fr) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Oligonucleotides antisens optimises pour cibler le rein
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
GB0719367D0 (en) 2007-10-03 2007-11-14 Procarta Biosystems Ltd Transcription factor decoys, compositions and methods
US9029337B2 (en) * 2007-11-09 2015-05-12 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
CN101984759A (zh) * 2007-11-09 2011-03-09 Isis药物公司 因子9表达的调节
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
CA2782375C (fr) * 2009-12-23 2023-10-31 Opko Curna, Llc Traitement de maladies associees a la proteine ucp2 (uncoupling protein) par inhibition du produit de transcription antisens naturel en ucp2
GB201002413D0 (en) 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201005545D0 (en) 2010-04-01 2010-05-19 Procarta Biosystems Ltd Transcription factor decoys
PL2585596T3 (pl) 2010-06-23 2021-06-28 Curna, Inc. Leczenie chorób związanych z podjednostką alfa kanału sodowego bramkowanego napięciem (SCNA) poprzez hamowanie naturalnego transkryptu antysensownego SCNA
PL3461895T3 (pl) 2012-06-25 2021-01-11 Ionis Pharmaceuticals, Inc. Modulacja ekspresji ube3a-ats
EP2931893A1 (fr) * 2012-12-13 2015-10-21 Universität Leipzig Modulation des lymphocytes t par saut d'exon
WO2016086104A1 (fr) 2014-11-25 2016-06-02 Ionis Pharmaceuticals, Inc. Modulation de l'expression du ube3a-ats
CA3004799C (fr) 2015-11-12 2024-05-14 F. Hoffmann-La Roche Ag Oligonucleotides pour induire l'expression paternelle d'ube3a
TWI809004B (zh) * 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
US11939582B2 (en) * 2018-08-20 2024-03-26 Rogcon, Inc. Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies
EP3947684A4 (fr) 2019-03-29 2023-09-20 Ionis Pharmaceuticals, Inc. Composés et méthodes de modulation de ube3a-ats

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6124133A (en) * 1999-10-15 2000-09-26 Isis Pharmaceuticals Inc. Antisense inhibition of fra-1 expression
DE60230641D1 (de) * 2001-09-14 2009-02-12 Oxford Biomedica Ltd Lentivirale vektoren zur behandlung von schmerzen

Also Published As

Publication number Publication date
CA2495398A1 (fr) 2004-02-26
BR0313455A (pt) 2007-07-31
WO2004016754A3 (fr) 2005-11-10
AU2003268096A8 (en) 2004-03-03
EP1578927A2 (fr) 2005-09-28
WO2004016754A2 (fr) 2004-02-26
JP2006507808A (ja) 2006-03-09
MXPA05001836A (es) 2005-04-19

Similar Documents

Publication Publication Date Title
AU2003281327A1 (en) Antisense modulation of tfg-beta 2 expression
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU2003237875A1 (en) Antisense modulation of apolipoprotein b expression
AU2001229493A1 (en) Antisense modulation of mekk2 expression
AU2003268096A1 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AU2002320525A1 (en) Antisense modulation of glioma-associated oncogene-2 expression
AU2002366788A1 (en) Antisense modulation of ship-1 expression
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2001283443A1 (en) Antisense modulation of hpk/gck-like kinase expression
AU2003257966A1 (en) Antisense modulation of lar expression
AU2002357102A1 (en) Antisense modulation of cd36l1 expression
AU2003297897A1 (en) Modulation of stat 6 expression
AU2002322551A1 (en) Antisense modulation of rip2 expression
AU2002347809A1 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
AU2003241496A1 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU2003243589A1 (en) Antisense modulation of smrt expression
AU2003230301A1 (en) Antisense modulation of dyrk4 expression
AU2003263836A1 (en) Antisense modulation of ptpra expression
AU2003236510A1 (en) Antisense modulation of ptpn12 expression
AU2003287180A1 (en) Antisense modulation of gfat expression
AU2003254258A1 (en) Antisense modulation of edg1 expression
AU2003247400A1 (en) Antisense modulation of ptprk expression

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase